Vol. 24, No. 1, 2006
Issue release date: December 2005
Free Access
Blood Purif 2006;24:107–114
(DOI:10.1159/000089446)
Paper
Add to my selection

Peritoneal Dialysis in Europe: An Analysis of Its Rise and Fall

Lameire N. · Peeters P. · Vanholder R. · van Biesen W.
Renal Division, University Hospital Ghent, Ghent, Belgium
email Corresponding Author


 goto top of outline Key Words

  • Renal replacement therapy
  • End-stage renal disease
  • Peritoneal dialysis

 goto top of outline Abstract

There is a wide variability in the utilization of peritoneal dialysis throughout Europe that cannot be explained by differences in medical factors alone. Over the last years, the utilization of peritoneal dialysis has even changed in individual countries. The main factors of this variation are not medical, but rather changes in reimbursement and other financial considerations. The overall structure of the health care in an individual country is to a large extent determining the use of a renal replacement therapy modality.

Copyright © 2006 S. Karger AG, Basel


 goto top of outline References
  1. Oreopoulos DG, Robson M, Faller B, Ogilvie R, Rapoport A, deVeber GA: Continuous ambulatory peritoneal dialysis: a new era in the treatment of chronic renal failure. Clin Nephrol 1979;11:125–128.
  2. Prichard S: Will peritoneal dialysis be left behind? Semin Dial 2005;18:167–170.
  3. Friedman EA: Critical appraisal of continuous ambulatory peritoneal dialysis. Annu Rev Med 1984;35:233–248.
  4. Shaldon S, Koch KM, Quellhorst E, Lonnemann G, Dinarello CA: CAPD is a second-class treatment. Contrib Nephrol 1985;44:163–172.
  5. Bloembergen WE, Port FK, Mauger EA, Wolfe RA: A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1995;6:177–183.
  6. Held PJ, Port FK, Turenne MN, Gaylin DS, Hamburger RJ, Wolfe RA: Continuous ambulatory peritoneal dialysis and hemodialysis: comparison of patient mortality with adjustment for comorbid conditions. Kidney Int 1994;45:1163–1169.
  7. Li PK, Law MC, Chow KM, Chan WK, Szeto CC, Cheng YL, Wong TY, Leung CB, Wang AY, Lui SF, Yu AW: Comparison of clinical outcome and ease of handling in two double-bag systems in continuous ambulatory peritoneal dialysis: a prospective, randomized, controlled, multicenter study. Am J Kidney Dis 2002;40:373–380.
  8. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, Kim YH, Kim YL, Kim DJ, Kim YS, Ahn C, Kim MJ, Shin SK: Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (balance). Perit Dial Int 2005;25:248–255.
  9. Collins AJ, Hao W, Xia H, Ebben JP, Everson SE, Constantini EG, Ma JZ: Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis 1999;34:1065–1074.
  10. Fenton SS, Schaubel DE, Desmeules M, Morrison HI, Mao Y, Copleston P, Jeffery JR, Kjellstrand CM: Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis 1997;30:334–342.
  11. Heaf JG, Lokkegaard H, Madsen M: Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrol Dial Transplant 2002;17:112–117.
  12. Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT: Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis 2. J Am Soc Nephrol 2003;14:2851–2860.
  13. Vonesh EF, Snyder JJ, Foley RN, Collins AJ: The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int 2004;66:2389–2401.
  14. Jaar BG, Coresh J, Plantinga LC, Fink NE, Klag MJ, Levey AS, Levin NW, Sadler JH, Kliger A, Powe NR: Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 2005;143:174–183.
  15. Van Biesen W, Vanholder R, Veys N, Lameire N: Peritoneal dialysis in anuric patients: concerns and cautions. Semin Dial 2002;15:305–310.
  16. Churchill DN, Taylor DW, Keshaviah PR, the Canada-USA Peritoneal Dialysis Study Group: Adequacy of dialysis and nutrition in chronic peritoneal dialysis: association with clinical outcomes. J Am Soc Nephrol 1996;7:198–207.
  17. Bargman JM, Thorpe KE, Churchill DN: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001;12:2158–2162.
  18. Szeto CC, Wong TY, Chow KM, Leung CB, Law MC, Wang AY, Lui SF, Li PK: Impact of dialysis adequacy on the mortality and morbidity of anuric Chinese patients receiving continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 2001;12:355–360.
  19. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002;13:1307–1320.
  20. Burkart JM: The ADEMEX study and its implications for peritoneal dialysis adequacy. Semin Dial 2003;16:1–4.
  21. Cueto-Manzano AM, Correa-Rotter R: Is high peritoneal transport rate an independent risk factor for CAPD mortality? Kidney Int 2000;57:314–320.
  22. Davies SJ, Phillips L, Russell GI: Peritoneal solute transport predicts survival on CAPD independently of residual renal function. Nephrol Dial Transplant 1998;13:962–968.
  23. Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Page D: Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1998;9:1285–1292.
  24. Brown EA, Davies SJ, Rutherford P, Meeus F, Borras M, Riegel W, Divino Filho JC, Vonesh E, van Bree M: Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. J Am Soc Nephrol 2003;14:2948–2957.
  25. Rodriguez-Carmona A, Fontan MP: Sodium removal in patients undergoing CAPD and automated peritoneal dialysis. Perit Dial Int 2002;22:705–713.
  26. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, Bosselmann HP, Heimburger O, Simonsen O, Davenport A, Tranaeus A, Divino Filho JC: Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003;14:2338–2344.
  27. Nissenson AR, Prichard SS, Cheng IK, Gokal R, Kubota M, Maiorca R, Riella MC, Rottembourg J, Stewart JH: Non-medical factors that impact on ESRD modality selection. Kidney Int Suppl 1993;40:S120–S127.
  28. Nissenson AR, Prichard SS, Cheng IK, Gokal R, Kubota M, Maiorca R, Riella MC, Rottembourg J, Stewart JH: ESRD modality selection into the 21st century: the importance of non-medical factors. ASAIO J 1997;43:143–150.
  29. Mehrotra R, Blake P, Berman N, Nolph KD: An analysis of dialysis training in the United States and Canada. Am J Kidney Dis 2002;40:152–160.
  30. Lameire N, Van Biesen W, Dombros N, Dratwa M, Faller B, Gahl GM, Gokal R, Krediet RT, La Greca G, Maiorca R, Matthys E, Ryckelynck JP, Selgas R, Walls J: The referral pattern of patients with ESRD is a determinant in the choice of dialysis modality. Perit Dial Int 1997;17(suppl 2):S161–S166.
  31. Mendelssohn DC, Mullaney SR, Jung B, Blake PG, Mehta RL: What do American nephrologists think about dialysis modality selection? Am J Kidney Dis 2001;37:22–29.
  32. Rubin HR, Fink NE, Plantinga LC, Sadler JH, Kliger AS, Powe NR: Patient ratings of dialysis care with peritoneal dialysis vs hemodialysis. JAMA 2004;291:697–703.
  33. Mehrotra R, Marsh D, Vonesh E, Peters V, Nissenson A: Patient education and access of ESRD patients to renal replacement therapies beyond in-center hemodialysis. Kidney Int 2005;68:378–390.
  34. Goovaerts T, Jadoul M, Goffin E: Influence of a pre-dialysis education programme (PDEP) on the mode of renal replacement therapy. Nephrol Dial Transplant 2005;20:1842–1847.
  35. De Vecchi AF, Dratwa M, Wiedemann ME: Healthcare systems and end-stage renal disease (ESRD) therapies – An international review: costs and reimbursement/funding of ESRD therapies. Nephrol Dial Transplant 1999;14(suppl 6):31–41.
  36. Horl WH, de Alvaro F, Williams PF: Healthcare systems and end-stage renal disease (ESRD) therapies – An international review: access to ESRD treatments. Nephrol Dial Transplant 1999;14(suppl 6):10–15.
  37. Lameire N, Joffe P, Wiedemann M: Healthcare systems – An international review: an overview. Nephrol Dial Transplant 1999;14(suppl 6):3–9.
  38. Mettang T: Changes in dialysis reimbursement regulations in Germany. Perit Dial Int 2004;24:526–527.
  39. Wauters JP, Uehlinger D: Non-medical factors influencing peritoneal dialysis utilization: the Swiss experience. Nephrol Dial Transplant 2004;19:1363–1367.
  40. Macron-Nogues F, Vernay M, Ekong E, Thiard B, Salanave B, Fender P, Allemand H: The prevalence of ESRD treated with renal dialysis in France in 2003. Am J Kidney Dis 2005;46:309–315.
  41. Rutkowski B: Changing pattern of end-stage renal disease in central and eastern Europe. Nephrol Dial Transplant 2000;15:156–160.
  42. Locatelli F, D’Amico M, Cernevskis H, Dainys B, Miglinas M, Luman M, Ots M, Ritz E: The epidemiology of end-stage renal disease in the Baltic countries: an evolving picture. Nephrol Dial Transplant 2001;16:1338–1342.
  43. Buturovic-Ponikvar J: Renal replacement therapy in Slovenia: 2003 annual report. Ther Apher Dial 2005;9:196–201.

    External Resources

  44. Vazelov ES, Krivoshiev SG, Antonov SA, Lazarov G: End-stage renal disease and peritoneal dialysis in Bulgaria. Perit Dial Int 2004;24:512–517.
  45. Mircescu G, Capsa D, Covic M, Caprioara MG, Gluhovschi G, Golea O, Ursea N, Garneata L, Cepoi V, Constantinovici N, Covic A: Nephrology and renal replacement therapy in Romania – Transition still continues (Cinderella story revisited). Nephrol Dial Transplant 2004;19:2971–2980.
  46. Van Biesen W, Vanholder RC, Veys N, Dhondt A, Lameire NH: An evaluation of an integrative care approach for end-stage renal disease patients. J Am Soc Nephrol 2000;11:116–125.
  47. Davies SJ, Van Biesen W, Nicholas J, Lameire N: Integrated care. Perit Dial Int 2001;21(suppl 3):S269–S274.
  48. Korevaar JC, Feith GW, Dekker FW, van Manen JG, Boeschoten EW, Bossuyt PM, Krediet RT: Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int 2003;64:2222–2228.
  49. Shih YC, Guo A, Just PM, Mujais S: Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients. Kidney Int 2005;68:319–329.

 goto top of outline Author Contacts

Norbert Lameire
Renal Division, University Hospital Ghent
185, De Pintelaan
BE–9000 Ghent (Belgium)
Tel. +32 9 240 4524, Fax +32 9 240 4599, E-Mail norbert.lameire@ugent.be


 goto top of outline Article Information

Number of Print Pages : 8
Number of Figures : 2, Number of Tables : 3, Number of References : 49


 goto top of outline Publication Details

Blood Purification

Vol. 24, No. 1, Year 2006 (Cover Date: December 2005)

Journal Editor: Leunissen, K.M.L. (Maastricht)
ISSN: 0253–5068 (print), 1421–9735 (Online)

For additional information: http://www.karger.com/BPU


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.